|
|
Active Org.- |
Originator Org.- |
Active Indication- |
Inactive Indication- |
Drug Highest PhaseClinical |
First Approval Ctry. / Loc.- |
First Approval Date20 Jan 1800 |
100 Clinical Results associated with CD3ε x PDL1 x 4-1BB x EGFRvIII
100 Translational Medicine associated with CD3ε x PDL1 x 4-1BB x EGFRvIII
0 Patents (Medical) associated with CD3ε x PDL1 x 4-1BB x EGFRvIII